Blackstone Life Sciences will provide up to $1.5B through 2028 to cover development costs for Pfizer's investigational monthly GLP-1 receptor agonist berobenatide. In exchange, Blackstone is eligible for milestone payments tied to regulatory approval and commercial sales. Pfizer retains full control and ownership.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
